(2022). Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY). Research and Practice in Thrombosis and Haemostasis.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Safety and Efficacy of Long‐term Emicizumab Prophylaxis in Hemophilia A with Factor VIII Inhibitors: A Phase 3b, Multicenter, Single‐arm Study (STASEY)."
Research and Practice in Thrombosis and Haemostasis 2022.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Safety and Efficacy of Long‐term Emicizumab Prophylaxis in Hemophilia A with Factor VIII Inhibitors: A Phase 3b, Multicenter, Single‐arm Study (STASEY)."
Research and Practice in Thrombosis and Haemostasis, 2022.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.